Attitudes and practices in the laboratory monitoring of conventional synthetic disease modifying anti-rheumatic drugs by rheumatologists and rheumatology trainees

Table 1 Demographic details of respondents, N = 150^#

	N (%)^a
Country of practice
Australia	53 (35)
USA	39 (26)
New Zealand	9 (6)
United Kingdom	9 (6)
Ireland	8 (5)
Other (7 or less responses)*	32 (21)
Sex
Male	84 (56)
Female	66 (44)
Years in rheumatology practice
< 2 years	7 (5)
2–5 years	32 (21)
6–10 years	28 (19)
11–20 years	40 (27)
> 20 years	43 (29)
Primary work setting
Private practice	48 (32)
Public practice	79 (53)
Evenly split between public and private	23 (15)

^aPercentages are all rounded to the nearest whole number (including 0 and 100) and thus some differing raw numbers show the same percent and non-0 raw numbers may show 0%
^#Demographic data unavailable for whole cohort (N = 221)
*Canada, Italy, Denmark, Latvia, Philippines, Bangladesh, Columbia, Dominican Republic, Ecuador, Finland, France, Germany, Greece, Honduras, India, Mauritius and Mexico

ISSN: 2520-1026